All In Biotech

Drug Trial Radar · NCT06226129

Gadopiclenol in Contrast Enhanced MRI of the Prostate

Gadopiclenol (Elucirem): A New Gadolinium Based Contrast Agent With High Relaxivity for Increased Contrast and Improved Differentiation of Clinically Significant Prostate Cancer on Contrast Enhanced MRI: A Prospective Study.

Last checked: Nov 20, 2026Latest source record: Jul 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Suspended

Status

Suspended

Enrollment

150

Planned (sponsor's estimate)

Start

Feb 14, 2024

Primary completion

Feb 1, 2027

Study completion Feb 1, 2028

Sponsor

Lead sponsor
Columbia UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Guerbet
First posted
Jan 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The fundamental aim of this study is to show that the novel contrast agent Gadopiclenol (Elucirem), with its high relaxivity, facilitates increased contrast enhancement and improved differentiation of clinically significant prostate cancer on Prostate MRI, as categorized by the PI-RADS v2 classification categories.

Conditions

  • Prostate Cancer

Interventions

  • GadopiclenolDrug

    Gadopiclenol for contrast enhanced MRI

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Blinded Radiology Review of Enhancement of Images, Graded 1-5Time frame: Through Study Completion (An Average of 1 Year Post-MRI)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Columbia University Irving Medical Center

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.